Abstract: An exemplary, highly integrated, SPM-based system for measuring the conductivity and/or force of substance under programmable engaging/stretching processes is described. A sample bias is applied across two electrodes. A substance to be measured is sandwiched between them. A first electrode is first brought relative to a second electrode (engaging) in programmable pathways that can be described as stretching distance versus time curves. The process of engaging the electrodes continues until a certain current reached, a certain force reached and whichever case happens first. The electrodes are then separated (stretching) in programmable pathways that can be described as stretching distance versus time curves. A periodic modulation can be applied to the engaging/stretching process to realize different stretch pathways. The sample bias across the electrodes is kept constant or swept in a programmable shape over time, described as a voltage-versus time curve.
Type:
Grant
Filed:
March 30, 2009
Date of Patent:
June 5, 2012
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: A method for encapsulating nucleic acids, particularly siRNAs, shRNAs, microRNAs, gene therapy plasmids, and other oligonucleotides in biodegradable polymers is disclosed, whereby the nucleic acids are formulated into reverse micelles composed of non-toxic and/or naturally-occurring lipids prior to nanoparticle formation by nanoprecipitation. This method can be coupled to other techniques that improve intracellular drug targeting, ultimately enhancing intracellular delivery of the aforementioned nucleic acids.
Type:
Grant
Filed:
October 5, 2009
Date of Patent:
June 5, 2012
Assignees:
The Brigham and Women's Hospital, Massachusetts Institute of Technologoy
Inventors:
Aleksandar F. Radovic-Moreno, Liangfang Zhang, Robert S. Langer, Omid C. Farokhzad
Abstract: Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating tissue, wound sites, and tumors in animals.
Type:
Grant
Filed:
December 6, 2007
Date of Patent:
May 29, 2012
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: Compounds of Formula I or II, and methods of making and using thereof, are described herein. M represents a macrolide subunit, n is a C1-6 group, optionally containing one or more heteroatoms, D is an alkyl or aryl group, A is a linking group connected to D, B is an alkyl, alkylaryl or alkylheteroaryl spacer group, ZBG is a Zinc Binding Group, R1, R2 and R4 are independently are selected from hydrogen, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkanoate group, a C2-6 carbamate group, a C2-6 carbonate group, a C2-6 carbamate group, or a C2-6 thiocarbamate group, R3 is hydrogen or —OR5, R5 is selected from a group consisting of Hydrogen, a C1-6 alkyl hgroup, a C2-6 alkenyl group, a C2-6 alkynyl group, C1-6 alkanoate group, C2-6 carbamate group, C2-6 carbonate group, C2-6 carbamate group, or C2-6 thiocarbamate group.
Abstract: Natural and synthetic compounds having a lactone structure methods for alleviation of pain, especially pain associated with disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. Initial studies have shown that patients can be taken off of morphine when the preferred alpha-methylene-gamma-butyrolactone is administered in a dosage of between 60 and 120 mg/day intramuscularly.
Type:
Grant
Filed:
April 18, 2005
Date of Patent:
May 29, 2012
Assignee:
Magnachem International Laboratories, Inc.
Inventors:
Federico M. Gomez, C. Federico Gomez Garcia-Godoy
Abstract: Disclosed are compositions and methods useful for targeting gC1q/p32 receptors. The disclosed targeting is useful for delivering therapeutic and detectable agents to cancerous cells, and to areas of inflammation.
Type:
Grant
Filed:
July 13, 2007
Date of Patent:
May 15, 2012
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: This present invention relates to methods for treating or attenuating pain in a patient. Specifically, the invention provides a method for attenuating pain in proximity to the site of an open wound or surgical incision comprising instilling a pharmaceutical composition comprising a capsaicinoid into the wound or incision, allowing the pharmaceutical composition to dwell for a predetermined period of time, and aspirating the wound or incision to remove the pharmaceutical composition. The invention also provides a method for attenuating pain in proximity to a joint comprising intra-articularly injecting a pharmaceutical composition comprising a capsaicinoid into the joint, allowing the pharmaceutical composition to dwell for predetermined period of time, and aspirating the joint to remove the pharmaceutical composition. In certain embodiments of the invention, the capsaicinoid is capsaicin.
Abstract: Compositions and methods for costimulating T cells (i.e., increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation ad effector functions of T cells and/or promoting T cell survival) are provided. Suitable compositions include variant B7-DC polypeptides, fragments and fusion proteins thereof. Variant B7-DC polypeptides have reduced binding affinity for the inhibitory PD-1 ligand and substantially retain the ability to costimulate T cells. Methods for using variant B7-DC polypeptides to stimulate immune responses in subjects in need thereof are provided.
Abstract: The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the cross-linking is performed by functionalization of one or more OR groups on the pre-polymer backbone with vinyl, followed by photopolymerization to form the elastic biodegradable polymer composition or material. Preferably, acrylate is used to add one or more vinyls to the backbone of the pre-polymer to form an acrylated pre-polymer. In various embodiments, acrylated pre-polymers are co-polymerized with one or more acrylated co-polymers.
Type:
Grant
Filed:
January 12, 2007
Date of Patent:
March 27, 2012
Assignee:
Massachusetts Institute of Technology
Inventors:
Christopher J. Bettinger, Joost P. Bruggeman, Lino Da Silva Ferreira, Jeffrey M. Karp, Robert S. Langer, Christiaan Nijst, Andreas Zumbuehl, Jason Burdick, Sonia J. Kim
Abstract: Hydrolytically degradable polymers in the form of biodegradable disposable medical devices for use in medicine and laboratories such as syringes, test tubes, catheters, tubing, trays, medical fabrics, and gloves are described. The devices are formed in whole or in part of a hydrolytically degradable polymer. In the preferred embodiment, the devices or structural components thereof degrade in a period of weeks to months, preferably within a year and more preferably within six months of exposure to aqueous solutions. Conventional hydrolytically degradable polymers may be utilized or these may be modified to increase mechanical or processing characteristics, for example, using a polyfunctional branching agent and/or a chain extending agent. In one embodiment, the hydrolytically degradable polymer is a member of a new class of polyesters comprising an aliphatic dicarboxylic acid, an aliphatic diol and optionally, one or more bifunctional fatty acids such as ricinoleic acid and/or castor oil.
Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal.
Abstract: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.
Type:
Grant
Filed:
April 27, 2006
Date of Patent:
March 6, 2012
Assignee:
Curis, Inc.
Inventors:
Anthony David Baxter, Edward Andrew Boyd, Maria Frank-Kamenetsky, Oivin Guicherit, Jeffery Porter, Stephen Price, Lee Rubin, John Harry Alexander Stibbard
Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.
Type:
Grant
Filed:
November 17, 2009
Date of Patent:
February 28, 2012
Assignee:
Sanford-Burnham Medical Research Institute
Inventors:
Jeffrey W. Smith, Fumiko Axelrod, Steven J. Kridel, Daniel Romo, Vikram Purohit, Gil Ma
Abstract: The invention provides polypeptides comprising inhibitor of apoptosis protein (IAP) family members, such as BmIAP initially derived from Bombyx mori BmN cells, and nucleic acids encoding them, and methods for making and using these compositions, including their use for inhibiting apoptosis.
Type:
Grant
Filed:
July 8, 2010
Date of Patent:
February 21, 2012
Assignee:
Sanford-Burnham Medical Research Institute
Inventors:
Qihong Huang, John C. Reed, Bruce D. Hammock, Quinn L. Deveraux, Susumu Maeda, Hiroko Maeda, legal representative
Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.
Abstract: The present invention relates to cell free assays for measuring receptor activity, especially for measuring a constitutive or a non-constitutive activity of frizzled re-ceptors and uses thereof. The present invention further concerns a method for measuring a constitutive or non-constitutive activity of a frizzled receptor and a method for obtaining an active frizzled receptor ligand.
Abstract: Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.
Type:
Grant
Filed:
May 8, 2008
Date of Patent:
February 21, 2012
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: A medical device for example a wound dressing having antibacterial and optionally, antifungal properties, are provided together with methods for making the device. An exemplary dressing includes a layer of silver-containing fabric, (optionally) a layer of absorbent material, and (optionally) a layer of flexible air-permeable and/or water-impermeable material. The dressing can be used for prophylactic and therapeutic care and treatment of skin infections and surface wounds (including surgical incisions), as a packing material, and as a swab for surface cleaning.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
February 21, 2012
Assignee:
Argentum Medical, LLC
Inventors:
A. Bartholomew Flick, Gregg Silver, Thomas Miller
Abstract: Organisms are provided which express enzymes such as glycerol dehydratase, diol dehydratase, acyl-CoA transferase, acyl-CoA synthetase ?-ketothiolase, acetoacetyl-CoA reductase, PHA synthase, glycerol-3-phosphate dehydrogenase and glycerol-3-phosphatase, which are useful for the production of PHAs. In some cases one or more of these genes are native to the host organism and the remainder are provided from transgenes. These organisms produce poly (3-hydroxyalkanoate) homopolymers or co-polymers incorporating 3-hydroxypropionate or 3-hydroxyvalerate monomers wherein the 3-hydroxypropionate and 3-hydroxyvalerate units are derived from the enzyme catalysed conversion of diols. Suitable diols that can be used include 1,2-propanediol, 1,3 propanediol and glycerol. Biochemical pathways for obtaining the glycerol from normal cellular metabolites are also described.